Common use of The Commission Clause in Contracts

The Commission. For the purpose of this Agreement, the Commission hereby represents and warrants that as a result of the Decision, it has the power and authority to act on behalf and in the name of the Participating Member States, in accordance with the terms set forth in this Agreement, for the following subjects: (a) Development of the Vaccine as described in Section 4; (b) Funding process as described in Section 7, except for the payments resulting from the obligations assumed directly by the Participating Member States as described in Sections 7.3 and 7.4. (c) Audit of costs, as described in Section 7.6. (d) Allocation, as described in Section 8.3. (e) Any other subject not specifically attributed to the Participating Member States according to Section 2.2. In all dealings concerning those subjects, the Commission represents and warrants that it has full power and authority to: (i) execute, deliver, and receive on behalf of the Participating Member States all notices, requests and other communications hereunder; (ii) act as the point of contact for the Participating Member States; (iii) facilitate communications between the Parties for the purposes of this Agreement; and (iv) take such other administrative actions on their behalf in connection with this Agreement as the Commission and the Participating Member States deem appropriate. In all dealings concerning those subjects, the Commission agrees on behalf of itself and the Participating Member States that AstraZeneca shall be entitled to act and rely upon any statement, request, notice or agreement made or given by the Commission. Subject to each Participating Member State being bound by Section 16 of this Agreement, the Commission may share with the Participating Member States all information, documentation, data and other materials received from AstraZeneca.

The Commission. Each of the foregoing conditions must be For the purpose of this Agreement, the Commission hereby represents and warrants that as a result of the Decision, it has the power and authority to act on behalf and in the name of the Participating Member States, in accordance with the terms set forth in this Agreement, for the following subjects: (a) Development of the Vaccine as described in Section 4; (b) Funding process as described in Section 7, except for the payments resulting from the obligations assumed directly by the Participating Member States as described in Sections 7.3 and 7.4. (c) Audit of costs, as described in Section 7.6. (d) Allocation, as described in Section 8.3. (e) Any other subject not specifically attributed to the Participating Member States according to Section 2.2. In all dealings concerning those subjects, the Commission represents and warrants that it has full power and authority to: (i) execute, deliver, and receive on behalf of the Participating Member States all notices, requests and other communications hereunder; (ii) act as the point of contact for the Participating Member States; (iii) facilitate communications between the Parties for the purposes of this Agreement; and (iv) take such other administrative actions on their behalf in connection with this Agreement as the Commission and the Participating Member States deem appropriate. In all dealings concerning those subjects, the Commission agrees on behalf of itself and the Participating Member States that AstraZeneca shall be entitled to act and rely upon any statement, request, notice or agreement made or given by the Commission. Subject to each Participating Member State being bound by Section 16 of this Agreement, the Commission may share with the Participating Member States all information, documentation, data and other materials received from AstraZeneca.